Liquidia and Sandoz have also extended the term of their promotion agreement for Treprostinil Injection until 2032 MORRISVILLE, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (Liquidia ...

An international, multisite phase 3 trial co-led by a University of Cincinnati researcher found Parkinson’s disease medication delivered through an infusion pump is safe and effective at reducing ...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has launched commercial sales of the ...

AbbVie’s bid to cannibalize its own Parkinson’s disease business has advanced, with the phase 3 success of subcutaneous, pump-delivered levodopa-carbidopa formulation ABBV-951 providing the backbone ...

Remunity Pump is intended for continuous subcutaneous delivery of Remodulin in prefilled cassettes for the treatment of PAH in adults aged ≥22 years. Remunity ® Pump for Remodulin ® (treprostinil; ...

ITCA650 is a unique formulation of exenatide currently in development, which delivers medication through an implantable subcutaneous pump delivery system. The osmotic mini pump provides a slow and ...